


**SUPPLEMENTAL TABLE A: Baseline Levels of Laboratory Measures**

	N	Losartan Median [IQR]	Placebo Median [IQR]
<i>Clinical Laboratory Measures</i>			
CD4+ count, cells/ $\mu$ L	108	451 [300, 496]	430 [321, 516]
CD8+ count, cells/ $\mu$ L	108	698 [491, 879]	683 [450, 948]
Creatinine, mg/dL	108	1.0 [0.9, 1.2]	1.1 [0.9, 1.2]
Potassium, mmol/L	108	4.2 [4.0, 4.4]	4.3 [4.0, 4.4]
AST/SGOT, U/L	108	27 [22, 33]	28 [22, 35]
ALT/SGPT, U/L	108	26 [19, 35]	28 [19, 40]
Platelets, $10^9$ /L	108	205 [176, 230]	192 [170, 236]
Hemoglobin, g/dL	108	14.1 [13.4, 15.0]	14.8 [13.6, 15.6]
White blood count, $10^9$ cells/L	108	5.0 [4.2, 5.8]	5.1 [4.2, 6.0]
<i>Soluble Proteins</i>			
IL-6, pg/mL	108	0.91 [0.67, 1.30]	1.04 [0.75, 1.41]
TNF-R1, pg/mL	108	1193 [1049, 1378]	1161 [1027, 1357]
sCD163, ng/mL	108	824 [578, 990]	711 [537, 890]
sCD14, ng/mL	108	1383 [1247, 1616]	1330 [1163, 1613]
Neopterin, pg/mL	108	9.48 [7.03, 12.49]	8.94 [7.25, 12.20]
D-Dimer, $\mu$ g/mL FEU	108	0.26 [0.13, 0.47]	0.23 [0.15, 0.31]
Hyaluronic acid, ng/mL	108	41.5 [27.7, 69.4]	39.8 [26.0, 75.3]
Beta-crosslaps, ng/mL	108	0.37 [0.28, 0.60]	0.40 [0.27, 0.54]
Galectin-3, ng/mML	108	8.69 [6.55, 10.08]	7.83 [7.07, 9.87]
NTproBNP, pg/mML	108	39.2 [17.1, 69.2]	27.1 [16.5, 77.5]
ST2, ng/mL	108	23.4 [17.6, 28.1]	23.2 [17.9, 27.7]
<i>Cellular Phenotypes</i>			
CD14 <sup>+</sup> CD16 <sup>-</sup> Monocytes, %	33	85.8 [83.5, 88.0]	80.3 [33.3, 84.2]
CD14 <sup>+</sup> CD16 <sup>+</sup> Monocytes, %	33	2.2 [1.5, 3.8]	1.5 [0.0, 2.5]
CD14 <sup>dim</sup> CD16 <sup>+</sup> Monocytes, %	33	2.9 [2.3, 3.8]	2.3 [0.0, 6.3]
CX3CR1 <sup>+</sup> Monocytes, %	33	6.4 [5.9, 10.5]	4.9 [1.9, 12.5]
CCR2 <sup>+</sup> Monocytes, %	33	88.9 [81.7, 90.3]	82.8 [75.2, 89.4]
CD4 <sup>+</sup> CD27 <sup>-</sup> CD45RO <sup>+</sup> EM T-cells, %	33	15.8 [10.2, 22.5]	24.4 [16.4, 38.8]
CD8 <sup>+</sup> CD27 <sup>-</sup> CD45RO <sup>+</sup> EM T-cells, %	33	20.9 [17.8, 27.6]	21.9 [13.9, 38.8]
CD4 <sup>+</sup> CD27 <sup>+</sup> CD45RO <sup>+</sup> CM T-cells, %	33	35.9 [28.0, 45.6]	44.7 [16.7, 48.2]
CD8 <sup>+</sup> CD27 <sup>+</sup> CD45RO <sup>+</sup> CM T-cells, %	33	20.9 [11.6, 31.6]	17.5 [8.3, 27.3]
CD4 <sup>+</sup> CD27 <sup>+</sup> CD45RO <sup>-</sup> naïve T-cells, %	33	42.2 [26.8, 50.5]	15.3 [13.0, 3.9.0]
CD8 <sup>+</sup> CD27 <sup>+</sup> CD45RO <sup>-</sup> naïve T-cells, %	33	21.6 [12.0, 27.5]	17.3 [6.8, 25.4]


*ALT=alanine aminotransferase; AST=aspartate aminotransferase; IL-6=interleukin-6; TNF-R1=tumor necrosis factor receptor 1; NTproBNP=N-terminal pro b-type natriuretic peptide; EM=effector memory; CM=central memory*

373 **SUPPLEMENTAL FIGURE A: Treatment Effect of Losartan on Monocyte Phenotypes**  
 374 **(n=33)**



375


376 **SUPPLEMENTAL FIGURE B: Treatment Effect of Losartan on T-cell Memory Subsets**  
 377 **(n=33)**



378

379 *Legend:* Forrest plots include point estimates reflecting the treatment effect over follow-up of  
 380 losartan versus placebo, with error bars reflecting 95% confidence intervals. Treatment effect is  
 381 reflected as the mean difference, with each cell subset measured as a percent of the total  
 382 monocyte or T-cell population, respectively. The mean change from baseline over follow-up  
 383 within active-losartan and placebo groups is shown to the right of the graphs for each of the  
 384 corresponding measures.

385 **SUPPLEMENTAL FIGURE C: Subjective Adherence**



386

387 **LEGEND:** Self-reported adherence is presented at 3-month intervals for participants  
388 randomized to losartan ('A') and placebo ('B'). Each bar reflects the self-reported adherence  
389 over the prior 3-month follow-up period; i.e., Month 3 reflects adherence from randomization  
390 until the month 3 visit. Adherence was collapsed into three groups as 100%, ≥50% but with  
391 some misuses, and any response reflecting <50% of days adherent.

392